Correspondence 0001213900-24-013602 from CHINA PHARMA HOLDINGS, INC. (CPHI) (CIK 0001106644) (CPHI)
CHINA PHARMA HOLDINGS, INC. (CPHI) (CIK 0001106644)
Date: Feb. 14, 2024 · CIK: 0001106644 · Accession: 0001213900-24-013602
AI Filing Summary & Sentiment
File numbers found in text: 333-276481
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Attention: Jessica Dickerson and Jason Drory RE: China Pharma Holdings, Inc. Registration Statement on Form S-3 Filed January 12, 2024 File No. 333-276481
Dear Ms. Dickerson and Mr. Drory,
China Pharma Holdings, Inc. (the “Company”) hereby requests that the above-captioned registration statement (the “Registration Statement”) be declared effective at 4:00 p.m., Eastern Time on Wednesday, February 14, 2024, or as soon thereafter as may be practicable.
We acknowledge that a declaration by the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, that the Registration Statement is effective does not foreclose the Commission from taking any action with respect to the Registration Statement. We further acknowledge that such a declaration of effectiveness does not relieve the Company from our full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement. We understand that we may not assert staff comments to the Registration Statement or the declaration of effectiveness by the Commission as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, please do not hesitate to contact Diana Huang, Company Secretary at hps@chinapharmaholdings.com, or Elizabeth F. Chen of Pryor Cashman LLP, outside counsel to the Company, at echen@pryorcashman.com (Tel: 212-326-0199).
Very truly yours,
/s/ Zhilin Li
Show Raw Text
CORRESP
1
filename1.htm
China Pharma Holdings, Inc.
Second Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China
February 14, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attention: Jessica Dickerson and Jason Drory
RE:
China Pharma Holdings, Inc.
Registration Statement on Form S-3
Filed January 12, 2024
File No. 333-276481
Dear Ms. Dickerson and Mr. Drory,
China Pharma Holdings, Inc.
(the “Company”) hereby requests that the above-captioned registration statement (the “Registration Statement”)
be declared effective at 4:00 p.m., Eastern Time on Wednesday, February 14, 2024, or as soon thereafter as may be practicable.
We acknowledge that a declaration
by the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, that the
Registration Statement is effective does not foreclose the Commission from taking any action with respect to the Registration Statement.
We further acknowledge that such a declaration of effectiveness does not relieve the Company from our full responsibility for the adequacy
and accuracy of the disclosure in the Registration Statement. We understand that we may not assert staff comments to the Registration
Statement or the declaration of effectiveness by the Commission as a defense in any proceeding initiated by the Commission or any person
under the federal securities laws of the United States.
If you have any questions,
please do not hesitate to contact Diana Huang, Company Secretary at hps@chinapharmaholdings.com, or Elizabeth F. Chen of Pryor Cashman
LLP, outside counsel to the Company, at echen@pryorcashman.com (Tel: 212-326-0199).
Very truly yours,
/s/ Zhilin Li
Zhilin Li
Chief Executive Officer, Interim Chief Financial Officer and President
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
cc:
Elizabeth F. Chen, Pryor Cashman LLP